Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has completed the acquisition of Aceragen, Inc. (“Aceragen”), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments. The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advancement of Aceragen’s pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones. The Company estimates annual peak sales potential of $650 million from the three current lead programs.

H.I.G. Capital, a global alternative investment firm, announced on Oct. 3, 2022 that its portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals, a UK provider of niche generic and branded specialty pharmaceuticals. The financial terms of the transaction have not been disclosed.Morningside is focused on developing and licensing niche generic pharmaceutical products, marketing over 160 stock keeping units across more than 80 product families and multiple therapeutic areas.

Hillenbrand, Inc., completed its acquisition of Linxis Group, a supplier of specialized equipment for the food, pharma and cosmetics industries. Linxis Group will be a part of the Coperion Food, Health and Nutrition division headed by Kevin Buchler as president, food, health and nutrition division, and Tim Cook as chief strategy and business development officer, Linxis. “We look forward to having a dedicated and committed partner at our side that will support and enhance the growth path we started several years ago,” Mr. Cook said.

Cytiva has acquired CEVEC Pharmaceuticals, a Germany-based provider of high-performance cell line development and viral vector manufacturing technologies, in a move that strengthens Cytiva's capabilities to offer biomanufacturing solutions.With this acquisition, Cytiva gains CEVEC’s scalable producer cell lines for vectors based on adeno-associated virus and adenovirus, two widely used vectors for gene therapy delivery, according to an Oct. 6, 2022 company press release. Cytiva also gains producer cell lines (PCLs) enabled by CEVEC's ELEVECTA technology, which promotes yield, scalability, and robustness in the manufacturing process.

Marksans Pharma entered into a Business Transfer Agreement with Tevapharm India yesterday, to acquire its business relating to the manufacture and supply of bulk pharma formulations in Goa, as a going concern on a slump sale basis, a statement from Marksans Pharma has notified.The statement said that the transaction is in cash consideration, and is expected to be finalised by 1st April, 2023, subject to the usual closing conditions. Marksans has agreed to retain the site employees with the existing terms of employment.